Skip to main content

Table 1 Reduction of Plasmodium berghei oocyst intensity in Anopheles albimanus by mAb A-140

From: An antibody against an Anopheles albimanus midgut myosin reduces Plasmodium berghei oocyst development

Treatment

Mosquitoes fed/group

Prevalence (% infected mosquitoes)

Mean number of oocysts/mosquito (Range)

% Reduction in oocyst intensity

P -value

(C+) mAb 13.1 (100 μg/ml)

114

54

2.3 (0–25)

83

< 0.0001

(C-) mAb A-78 (100 μg/ml)

104

82

14.2 (0–142)

0

(C-) mAb A-78 (200 μg/ml)

59

83

10.8 (0–139)

0

mAb A-140 (100 μg/ml)

104

71

4.3 (0–50)

69.2

< 0.0001

mAb A-140 (200 μg/ml)

60

53

2.2 (0–30)

78.9

< 0.0001

  1. Transmission reduction efficiency of mAb A-140 was evaluated at two different doses and compared to anti-P28 mAb 13.1 (positive control, C+) and mAb A-78 (negative control, C-), which was raised against An. albimanus midguts but was determined previously to have no functional activity against the parasite. P-values as determined by a zero-inflated GLMM statistical methods (see Additional file 1 for details) in comparisons with matched concentrations of mAb A-78 (100 μg/ml or 200 μg/ml). A representative dataset is shown below from replicate studies. Data correspond to Fig. 1d